Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.
about
Flavaglines alleviate doxorubicin cardiotoxicity: implication of Hsp27Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancerTreatment including anthracyclines versus treatment not including anthracyclines for childhood cancerCardiotoxicity in childhood cancer survivors: strategies for prevention and managementA functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinityResearch progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.Oxygen in human health from life to death--An approach to teaching redox biology and signaling to graduate and medical studentsUtility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicityDifferential mitochondrial toxicity screening and multi-parametric data analysisChemotherapy-Induced Cardiotoxicity: Pathophysiology and PreventionAssessing the Cardiac Toxicity of Chemotherapeutic Agents: Role of Echocardiography.Cardio-oncology: a new medical issue.Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone.Transcriptome profiling of peripheral blood cells identifies potential biomarkers for doxorubicin cardiotoxicity in a rat modelThe minipig as a new model for the evaluation of doxorubicin-induced chronic toxicity.Interindividual variability in the cardiac expression of anthracycline reductases in donors with and without Down syndrome.Pregnancy in a patient with cancer and heart failure: challenges and complexities.Assessment of cardiotoxicity with cardiac biomarkers in cancer patients.Cardiovascular Late Effects and Exercise Treatment in Breast Cancer: Current Evidence and Future DirectionsCardiomyocyte specific ablation of p53 is not sufficient to block doxorubicin induced cardiac fibrosis and associated cytoskeletal changesCardiovascular disease in adult survivors of childhood cancer.S-diclofenac protects against doxorubicin-induced cardiomyopathy in mice via ameliorating cardiac gap junction remodelingSchisandrin B prevents doxorubicin-induced chronic cardiotoxicity and enhances its anticancer activity in vivo.Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy.Protective effect of guggulsterone against cardiomyocyte injury induced by doxorubicin in vitroAnthracycline cardiotoxicity: from bench to bedside.Cardiovascular effects in childhood cancer survivors treated with anthracyclines.Anthracycline-associated cardiotoxicity in survivors of childhood cancer.Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cellsEffect of Supplementation of Tanshinone IIA and Sodium Tanshinone IIA Sulfonate on the Anticancer Effect of Epirubicin: An In Vitro Study.Anthracycline treatment and ventricular remodeling in left ventricular assist device patients.Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin.A conserved antioxidant response element (ARE) in the promoter of human carbonyl reductase 3 (CBR3) mediates induction by the master redox switch Nrf2CaMKII-dependent SR Ca leak contributes to doxorubicin-induced impaired Ca handling in isolated cardiac myocytes.Dexrazoxane as a cardioprotectant in children receiving anthracyclinesAnthracycline-induced cardiomyopathy in a dog treated with epirubicin.Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood.Curing Cancer, Saving the Heart: A Challenge That Cardioncology Should Not Miss.Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.Melissa officinalis Protects against Doxorubicin-Induced Cardiotoxicity in Rats and Potentiates Its Anticancer Activity on MCF-7 Cells
P2860
Q21135010-B8FA16AD-A426-4C62-9B96-F052AA469F72Q24234833-0FE3E101-85CC-4CA9-979B-D6C120BA3660Q24241602-F95E0D02-AA2C-42B6-AF32-C1AB6F270FF2Q24628695-A006898D-C25B-44FB-B30B-B2E5A1FE0FBCQ24647984-C11DB4FA-5489-477A-A841-0C5354B5FA50Q26742059-52BCCEBE-80E3-4B50-97F7-0E31EADC07C7Q26998478-8A1A6B27-6039-4B67-9350-9605AD9E2A01Q28301317-8E629372-C7D4-4B69-BDE5-A30B28E2DCE0Q28484406-D0D56009-FCDA-4FD7-B904-DEF2D2F7D130Q30399577-94E1293B-CB42-4666-A6F0-145BB656AAF5Q30446509-A992EF14-BB2C-4279-8467-32DE30E949C0Q30471284-EA83EBF3-017C-46DB-9149-CD95D649680DQ33341069-992001E2-E4CB-49A9-A67F-ED6C869183F6Q33404672-CDDC0F19-09B6-42AD-AF6F-E412F5E7605AQ33427938-B0E6A49C-39C9-43A7-A33B-65F41D70173DQ33784640-0DBEC210-589A-4CFA-A435-F6DB61BC8AB6Q33885550-83EB82C7-EB7F-408A-AD0D-4FBCE4F1013AQ33896047-0EEEA166-892F-41AB-BC20-5933CEDE83EBQ33907581-AD8E1C59-F30F-4919-8E30-1B848596DFBEQ33987908-CF5FFBC7-55B7-4D9F-89C8-A2AD22A5DC83Q34042984-47383B74-39CA-4A80-AE9C-A715F287AE35Q34062431-802DC940-B77F-4CF4-B842-A555F7341546Q34099183-0CFCE4E7-03C9-417B-8ABB-826F1029207AQ34322162-E27FC48C-E4E2-4D7D-8C21-C328EBE82720Q34392758-E8B00CCE-4194-4962-ACA0-E66795936755Q34477415-36C246B4-9D7F-45A7-83A2-8273C401E2DFQ34572109-208CBD95-12F0-4DB7-ADC1-A3751A1E6582Q34626238-29E5E518-0E28-442A-89E4-A25D2F6642FFQ35014803-92DACC94-7133-450B-9E65-83763A73208CQ35055130-BE80A353-E11A-4B62-96A9-6A93CE1FB46BQ35246219-57007A51-7DF9-4A27-BED7-4B3864ED9106Q35550223-DCE2C1E6-5E8D-4FAF-BDA4-B1D43537C8B5Q35577174-BBAF4407-4B47-45F2-9D7B-C99305821A3BQ35580896-BD45233D-2546-4A08-A7D4-1C4906122556Q35583768-4D01B187-0C0C-413C-8227-70C06E076D0EQ35604952-3D27B998-66F2-43BB-91F4-A747046E2E82Q35757419-C0F1B7FC-DB36-49C3-8346-1200912B8623Q35997676-BBF2845C-5C1E-4A6A-9674-4178A47143ECQ36058273-A9580268-E0F1-404E-AD67-2D706EE43FADQ36202577-6167FF25-44DA-4FDC-A1D0-897AB2BA57DD
P2860
Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Protecting against anthracycli ...... the most promising strategies.
@ast
Protecting against anthracycli ...... the most promising strategies.
@en
Protecting against anthracycli ...... the most promising strategies.
@nl
type
label
Protecting against anthracycli ...... the most promising strategies.
@ast
Protecting against anthracycli ...... the most promising strategies.
@en
Protecting against anthracycli ...... the most promising strategies.
@nl
prefLabel
Protecting against anthracycli ...... the most promising strategies.
@ast
Protecting against anthracycli ...... the most promising strategies.
@en
Protecting against anthracycli ...... the most promising strategies.
@nl
P2093
P2860
P1476
Protecting against anthracycli ...... the most promising strategies.
@en
P2093
Eugene H Herman
Karlijn A Wouters
Leontien C M Kremer
Steven E Lipshultz
Tracie L Miller
P2860
P304
P356
10.1111/J.1365-2141.2005.05759.X
P407
P577
2005-12-01T00:00:00Z